Lisa_Grimm

LISA G. GRIMM
3 Cornwall Drive East Windsor, New Jersey 08520
609-371-4751 lisaggrimm@gmail.com
Summary
Experienced Scientist with strong emphasis in the therapeutic areas of Immunology, Oncology,
Haemostasis and Biologics. Diverse technical experience developing, optimizing, validating and
implementing immunoassays, cell based assays and coagulation assays on various platforms.
Technical Experience:
Immunoassys and Immunogenicity Assays: Flow Cytometry (FACScan, FACS Calibur, FACS
Canto), ELISA, ELISpot, Cytometric Bead Array (CBA), electrochemiluminescene (ECL) based
multiplex ELISA (MSD Platform), Tetramer staining, Luminex FlexMap3D/Bio-Plex 200 (multiplex
bead platform), Anti-drug antibody (ADA) assays, identification of antibody pairs (ForteBio),
pharmacokinetics (PK)
Cell-based Assay Development: Lymphocyte isolation, purification and activation, Cytotoxic T
Lymphocyte assays (CTL), dendritic cell maturation, in vitro and ex vivo assay development and
optimization, cell based neutralizing antibody (NAb) assays. Culture primary and established
human, primate and murine cells.
Proliferation, Viability and Cytotoxicity Assays: CFSE (Carboxyfluoresceine diacetate
succinimidyl ester), MTT and CellTiter Blue® viability assays, Annexin V/PI staining, chromium
release and thymidine uptake assays
Radioisotopes: Cr51, I125, I131, Y90
Molecular Biology: SDS-PAGE and Western Blot
Platelet Methodology: Platelet activation and aggregation; washed platelet, platelet rich plasma
(PRP) and platelet poor plasma (PPP) preparations, whole blood studies
Clinical and research coagulation instrumentation: (ACL 8000), Thrombelastograph (TEG),
Hemodyne, Thrombin Generation (CAT), Chrono-Log Platelet Aggregometer
In Vivo (rat and murine): Intraperitoneal, subcutaneous, intravenous, intratesticular and
intraplantar injections, oral dosing, necropsy, retro-orbital bleeding and cardiac puncture,
xenograft and reconstitution models
Professional Experience:
Tandem Labs, West Trenton, NJ 2012-present
Research Scientist/Team Lead
Member of the Immunoanalytical group responsible for the development, optimization and validation of
methods and screening of clinical samples in multiple immunoassays and immunogenicity assays under
GLP regulations.
• Routinely screen pre-clinical and clinical samples in immunogenicity, anti-drug antibody (ADA)
and neutralizing antibody (Nab), assays to meet the client needs and tight deadlines for data
submission.

LISA G. GRIMM
• Involved in the validation of several ADA and Nab method transfers to screen samples for the
presence of antibodies against enzyme replacement drug therapies (ERT) for the treatment of
lysosomal storage diseases.
• Optimize and validated multiple multiplex ECL immunoassays and multiplex bead immunoassay
Page 2 of 7
for biomarker assessment post therapeutic treatment.
• Meet with clients to discuss projects, train on method transfers and write method protocols
following a GLP format.
• Develop, optimize and validate pharmacokinetic (PK) studies to quantitatively measure large
molecule drug therapy in patient samples for client FDA submission.
• Work closely with colleagues in the daily activities of the laboratory. Provide scientific support,
answer questions, review deviations, train new employees, maintain a cohesive work
environment and promote teamwork.
• Contribute to data discussions involving method development or troubleshooting methods that
may become problematic during sample analysis.
• Modified all cell based SOP’s to meet common cell culture procedures.
• Maintain all cell culture laboratory instruments (biosafety cabinets, incubators and microscopes).
PPD, Inc, Middleton, WI 2011-2012
Associate Research Scientist
Consultant at Bristol Myers Squibb in the Bioanalytical Science-Biomarker Group
• Contributed to the development and validation of multiplex immunoassays to screen clinical
patient samples for effectiveness of large molecule drug therapy.
• Identified antibody pairing on the ForteBio to develop immunoassays utilizing the most optimal
antibody pairs
• Screened supernatants and purified antibodies to identify peptide specificity for the development
of a diagnostic biomarker assay for the treatment of Alzheimer’s disease.
• Collaborated with colleagues to meet tight project deadlines.
• Conjugation of peptides and antibodies to BioPlex/Luminex microspheres.
• Developed a Luminex bead assay to monitor the quality of air during the manufacturing process
of a large molecule drug therapy.
XENOBIOTICS LABORATORIES, Inc. Plainsboro, NJ 2009-2011
Member of the Biological Service group responsible for the development, identification and validation of
cell based assays ex vivo proliferation assays and biomarker immunoassays under GLP regulations.
• Conducted experimentation in compliance with 21 CFR Part 11 and the FDA Bioanalytical Method
Validation Guidance.

LISA G. GRIMM
• Developed and optimized an ex vivo proliferation assay to monitor cytokine release post
immunization of mice monitoring the performance of an immunomodulator protein therapy drug for
the treatment of multiple sclerosis for a sponsor IND submission.
• Routinely developed, optimized and validated biomarker immunoassays.
• Prepared project proposals presented to the Management Team to broaden the scope of the
Page 3 of 7
Biological Service Group.
• Identified biomarkers relevant to various therapeutic indications based on sponsor needs and
subsequent sample analysis.
• Laboratory Supervisor of the tissue culture lab to ensure proper function and maintenance of
laboratory equipment.
• Performed quality control (QC) audit of data, documents and reports.
• Provided support and guidance to scientists pertaining to laboratory safety, proper handling of
samples, troubleshooting, assay development and validation.
JOHNSON AND JOHNSON. Raritan, NJ 2009-2009
Scientist, contract
Member of the Mechanistic Toxicology group responsible for the development and identification of assays
monitoring toxicity with a primary focus on kidney toxicity.
• Rapidly evaluated novel kidney biomarkers to ascertain potential safety liabilities in an active drug
development program resulting in performance award.
• Identified additional biomarkers more relevant to kidney toxicities/injury.
• Performed ECL based ELISA utilizing MSD Platform to analyze kidney biomarkers.
• Identified methods of analyzing n-acetyl alpha-D glucosaminidase (NAG) in tissue homogenates
via western blot analysis, commercially available assay kits and modifications of these kits to
identify levels of n-acetyl alpha-D glucosaminidase isoenzymes (HEXA and HEXB).
• Assisted in rat models of toxicity.
NOVO NORDISK, Inc. North Brunswick, NJ 2005-2008
Research Scientist (2007-2008)
Associate Research Scientist (2005-2007)
Member of the Hemostasis Physiology group responsible for the development and identification of assays
for the monitoring of hemostasis and coagulation.
• Developed washed platelet protocol for the use in screening peptides to enhance platelet
aggregation resulting in an approved project proposal.
• Established modifications to clinical assays to screen fusion proteins increasing coagulation for
hemophilia indication resulting in a new project approved by upper management.
• Developed whole blood, platelet rich plasma (PRP) and washed platelet protocols for flow
cytometric analysis identifying the binding of proteins to platelet receptors and the ability to
activate platelets.

LISA G. GRIMM
• Evaluated the effects of FVIIa in a modified thrombin generation assay and other clinical
Page 4 of 7
coagulation instruments for use in clinical studies taking place at Novo Nordisk, Inc.
• Performed verification/validation (ANOVA) protocols on research and clinical coagulation
instruments (ACL 8000, TEG, Hemodyne, CAT)
• Organized internal blood donations and identified an external blood supplier to ensure
colleagues obtained quality and sufficient blood volumes for their research projects.
PROTALEX, INC. New Hope, PA 2004-2005
Performed various in vitro assays to identify the mechanism of action (MOA) of protein targets for the
treatment of autoimmune diseases within the Immunology Group.
• Optimized an in vitro assay using human peripheral blood mononuclear cells (PBMCs) to
determine the MOA of a known protein for the therapeutic use in autoimmune diseases.
• Analyzed the binding properties of fluorescent-labeled proteins on primary cell populations of
human and monkey PBMCs.
• Determined the effects of a purified form of staphylococcal bacteria protein known as Protein A
(PRTX-100), on cell surface molecules, proliferation, inflammatory cytokine release and
apoptosis resulting in the submission of an IND
• Optimized cell culture conditions of human monocytic cell lines to determine the effects of PRTX-
100 on cell surface markers and the secretion/shedding of cytokines and receptors.
• Determined the effects of the PRTX-100 on cell signaling pathways.
• Assisted laboratory set up, maintenance and organization.
• Trained scientists on proper record keeping.
PURDUE PHARMA, Cranbury, NJ 2000-2004
Scientist
Performed various in vivo, ex vivo and in vitro assays to identify novel protein cancer targets for the
oncology program within the Immunotherapeutics department.
• Assisted in reconstitution of severe combined immune deficient SCID mice with the intent to
develop a mouse model capable of eliciting an immune response to tumor specific peptides to
generate in vivo production of therapeutic human monoclonal antibodies.
• Initiated the development and optimization of a human and murine model of active
immunotherapy of cancer to monitor efficacy and safety.
• Developed and optimized several in vitro immunomodulatory assays including dendritic cell
maturation, T cell education (IVE), Cytotoxic T-Lymphocyte (CTL), Tumor antigen specific TCR
analysis by tetramer staining and ELISpot for cancer vaccine development.
• Identified various human cell lines positive for CA125 cell surface expression to establish a
xenograft murine model for determining therapeutic efficacy of novel protein cancer targets
resulting in a development candidate.

LISA G. GRIMM
• Routinely presented experimental findings to management and project team members and
Page 5 of 7
contributed to publications and abstracts.
WYETH-AYERST RESEARCH LABORATORIES, Princeton, NJ 1996-2000
Scientist II
Performed various in vivo and in vitro assays for the Oncology/Immunoinflammatory Disease group to
identify and validate potent novel MMP/TACE compounds focusing on the efficacy of these compounds to
inhibit shed TNF alpha, p55 and p75 cytokines for the treatment of osteoarthritis, rheumatoid arthritis and
systemic inflammation.
• Assisted in the characterization of a novel osteoarthritis transgenic murine model.
• Independently developed and optimized several in vitro assays, i.e. cell surface staining,
antibody bound T cell proliferation assays, utilizing primary murine cells and established human
cell lines.
• Reviewed pertinent literature as basis for developing, troubleshooting and establishing novel
techniques.
• Wrote detailed experimental protocols.
• Analyzed and presented data and discussed future goals at group meetings.
• Proven record of independent performance, adaptability, flexibility and functioning as a
dependable team player.
THE LIPOSOME COMPANY, Inc, Princeton, NJ 1994-1996
Research Associate
RIDER UNIVERSITY, Department Of Biology, Lawrenceville, NJ 1992-1994
Research Assistant
Awards
Bristol Myers Squibb Lab Olympics Gold Medal Award (2011, awarded by the BAS-Biologics Director for
outstanding technical abilities)
Johnson and Johnson Encore Award (2009, awarded by the compound team leader for significant
contributions in advancing drug candidates)
Wyeth-Ayerst Research Teamwork Award (1999, outstanding achievement meeting departmental goals)
Computer Experience
Proficient in MacIntosh and IBM applications including Cell Quest/Cell Quest Pro, DIVA (Becton
Dickinson) flow cytometry software, FLOW JO Software, Microsoft Office, GraphPad Prism, ELN
(Electronic Notebook System), Watson LIMS, SoftMax Pro, Discovery Workbench, Bio-Plex Manager,
Xponent FlexMap 3D software

LISA G. GRIMM
Page 6 of 7
Education
B.S., Biology, Rider University, Lawrenceville, NJ
Professional Development
Immunology Course, AAI, Philadelphia PA April14-19 2012
Manuscripts
Berger, M.A., Masters, G.R., Singleton J.,Scully, M.S., Grimm L.G., Soltis, D.A., Albone, E.F..
Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine
model of human ovarian cancer. Cancer Biother Radiopharm. 2005 Dec;20(6):589-602.
Wang, B., Berger, M., Masters, G., Albone, E., Yang, Q., Sheedy, J., Kirksey, Y., Grimm, L., Singleton, J.,
and Soltis, D.. Radiotherapy of Human Xenograft NSCLC Tumors in Nude Mice with an 90Y-labeled Anti-
Tissue Factor Antibody. Cancer Biotherapy & Radiopharmaceuticals (2005).
Julius P Jr, Kaga M, Palmer Y, Vyas V, Prior L, Delice D and Riggs J.,. Recipient age determines the
success of intraperitoneal transplantation of peritoneal cavity B cells. Immunology. 91, 383-390 (1997).
Riggs, J.E., Prior, L.G., Sirken, G.R., and Hobbs, M.V.. The Autologous Mixed Lymphocyte Response:
Distribution of Stimulator Cells. J. Autoimmunity 8, 21-31 (1995).
Riggs, J.E., Maurio, F.P., Prior, L.G., Sirken, G.R., and Hobbs, M.V.. The Autologous Mixed Lymphocyte
Response: Delayed T Cell Tolerance to B Cells in XID Mice. Cellular Immunology 157, 542-548 (1994).
Prior, L., Pierson, S., and Riggs, J.. Rapid Reconstitution of B cell function in XID mice by intravenous
transfer of immunoglobulin allotype-disparate peritoneal cavity B cells. Immunology 83, 180-183 (1994).
Abstracts
Christine Rivera, Jamil Hantash, Tony Joaquim, Renee Louis, Gerard Dalglish, and Lisa Grimm, The
Development and Validation of an Ultra Sensitive ELISA Method for the Determination of Tartrate-Resistant
Acid Phosphate 5 (TRAP) in Human Serum. AAPS-National Biotech Conference, San Diego, CA, 2014.
David Stewart, George Green, Flora Berisha, Steve Piccoli, Oi Wang, Paul Rhyne, Suk Kwok, Lisa Grimm,
Carol Gleasson, Pankaj Oberoi, Jim Wilbur, Robert J. Neely, Adam Simon, Holly D. Soares. Performance
of Improved CSF Ab42 and Tau assays in differentiating AD and MCI from control subjects. Alzheimer's
Association International Conference, Vancouver, 2012.
Robert Neely, Lisa Grimm, Flora Berisha, Oitak Wong, Ed Halk, and Paul Rhyne. Acceleration Of
Monoclonal Antibody Clone Selection Using A High Throughput Multiplexed Screening Method. AAPS-National
Biotech Conference, San Diego, CA, 2012.
King V, Grimm L, Pusateri AE. Applicability of a Thrombin Generation Test in Laboratory Screening. J
Thromb Haemost 2007; 5 Supplement 2: P-T-112

LISA G. GRIMM
John Pappas, Nancy Quan, Lisa Grimm, Sima Patel, Charlie Chen, Marc Berger, Lynda Tussey, Namit
Ghildyal. Comparison and Optimization of Human Dendritic Cell Maturation Conditions for in vitro T Cell
Education. Experimental Biology, Washington D.C., April 17-22, 2004.
Ahmad, I., Filep, J., Franklin, C., Janoff, A., Maurio, F., Prior, L., Zha, Y., and Mayhew, E.. Effects of Ether
Lipid liposomes against mouse tumors and human tumor xenografts. Proc. Am. Assoc. Cancer Res. (1996).
Ahmad, I., Ali, S., Dank, E., Filep, J., Franklin, C., Janoff, A., Minchey, S., Peters, A., Prior, L., and Mayhew,
E.. 1996. Preclinical anticancer effects of 2-bromo-hexanoyl paclitaxel (2’ Br-HTD) liposomes. Proc. Am.
Assoc. Cancer Res.
Ali, S., Ahmad, I., Dank, E., Filep, J., Franklin, C., Janoff, A., Minchey, S., Peters, A., Prior, L., and Mayhew,
E. 1995 Hydrophobic taxane derivatives for entrapment in liposomes. Conference on Formulation and Drug
Delivery, American Chemical Society. Boston, MA.
Prior, L., Glysing-Jensen, T., Suppiah, K., and Riggs, J. 1995. Immunodeficient Mouse Models for studies
of Lymphomagenesis. New Jersey Commission for Cancer Research Meeting Merck and Co., Inc.,
Whitehouse Station NJ, March 4.
Riggs, J., Julius, P., Prior, L., Depalma, D., and Hobbs, M.. 1995. T Cell Tolerance Broken by Restimulation
in the Autologous Mixed Lymphocyte Reaction. The 9th International Congress of Immunology. San
Francisco, CA, July 23-28.
Riggs, J., Prior, L., Julius, P., Palmer, Y., Thompson, K., and Pierson, S.. 1993. Murine Models for B Cell
Lymphomagenesis. New Jersey Commission for Cancer Research Meeting. UMDMJ-Robert Wood
Johnson Medical School, Piscataway, NJ, November 13.
Maurio, F., Sirken, G., Prior, L., and Riggs, J.. 1993. Neonatal T Cell Proliferation Induced by Peritoneal
Cavity and Peyer’s patch B Cells. American Assoc. Immunologists Meeting, Denver, CO, May 23.
Riggs, J., Prior, L., and Pierson, S.. 1992. Murine Models for B Cell Lymphomagenesis. New Jersey
Commission for Cancer Research Meeting, Rider College, Lawrenceville, NJ, November 21.
Page 7 of 7

Lisa_Grimm

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Similar to Lisa_Grimm

Similar to Lisa_Grimm (20)

Lisa_Grimm